What's Happening?
Sanofi is actively recruiting a Corporate Affairs Vaccines Lead for Poland and the Central South Europe Multi-Country Organization (CSE MCO). This hybrid Public Affairs and Communications role is central to shaping the policy and communications environment
to support vaccine launches and increase immunization uptake across the region. The successful candidate will be responsible for designing, leading, and executing integrated Public Affairs and Communications strategies for vaccines in Poland, aligning with business priorities and launch requirements. Key responsibilities include shaping healthcare policy to favor national immunization program inclusion and expansion, reimbursement, and tender processes for priority vaccines such as RSV, meningococcal, pneumococcal, and adult immunization. The role also involves building strategic relationships with external stakeholders, monitoring the policy landscape, and developing communication plans, including disease awareness programs. Additionally, the lead will coordinate regional strategies across the CSE MCO, facilitate knowledge sharing, and act as the primary contact point between CSE MCO and global Public Affairs and Communications teams for vaccines.
Why It's Important?
This role is critical for Sanofi's strategic objectives in the vaccines sector, particularly in expanding its portfolio and ensuring broad immunization uptake in Poland and the CSE MCO. The focus on shaping healthcare policy and engaging with key stakeholders highlights the complex interplay between pharmaceutical innovation, public health policy, and market access. By advocating for improved vaccination policies and processes, Sanofi aims to address public health challenges and contribute to disease prevention on a larger scale. The emphasis on adult immunization and new vaccines like RSV underscores the evolving landscape of vaccine development and the need for robust public affairs efforts to ensure their adoption. For the region, a successful Corporate Affairs Vaccines Lead can help overcome vaccine hesitancy, improve public health outcomes, and ensure equitable access to essential vaccines, ultimately impacting the health and well-being of millions.
What's Next?
The immediate next step is the successful recruitment of a qualified individual for this pivotal role. Once appointed, the Corporate Affairs Vaccines Lead will begin to implement and refine strategies for vaccine policy and communications in Poland and across the CSE MCO. This will involve active engagement with government bodies, health authorities, policymakers, media, and patient advocacy groups to advocate for Sanofi's immunization agenda. The lead will also focus on supporting the launch of new vaccines and ensuring their inclusion in national immunization programs and reimbursement schemes. Ongoing monitoring of the policy and regulatory environment will be crucial to anticipate risks and opportunities. The role will also involve facilitating cross-country learning on vaccine hesitancy mitigation and disease awareness campaigns, leveraging best practices to amplify Sanofi's voice and impact across the region.
Beyond the Headlines
The creation of such a specialized role by Sanofi reflects a broader industry trend where pharmaceutical companies are increasingly investing in sophisticated public affairs and communications strategies to navigate complex healthcare ecosystems. Beyond the commercial aspects, this role has significant public health implications. Effective advocacy and communication can play a crucial part in building public trust in vaccines, combating misinformation, and ensuring that scientific advancements translate into tangible health benefits for communities. The focus on adult immunization, often overlooked compared to childhood vaccination, points to a growing recognition of the importance of lifelong vaccination. This role also highlights the challenges and opportunities of operating in diverse multi-country organizations, where strategies must be tailored to local specificities while maintaining regional coherence. The success of this position could serve as a model for how pharmaceutical companies can effectively engage with public health stakeholders to drive positive health outcomes.
